chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, Arthralgia, Blood fibrinogen increased, Blood lactic acid, Brain natriuretic peptide normal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/25, Pfizer dose #1 04/15, Pfizer, dose #2 12/23, Pfizer, dose #3 1/1 COVID swab, result: detected 12/22 pt cc: exposure: unknown 1/1 pt admit Medicine cc: chest/neck/shoulder pain dx: chest pain, covid LOS: 3 days 1/1 TROPONIN I: 0.047 1/1 CRP: 1.621 1/1 CXR IMPRESSION: No pleural effusion or pneumothorax is identified. There is a 1.0 cm nodular density in the left lower lung which could reflect the patient's left nipple. Repeat study with nipple markers is recommended for confirmation to exclude a pulmonary lesion. Cardiomediastinal contours appear within normal limits. 1/2 CTA PE IMPRESSION: 1. No evidence of pulmonary embolism or other acute abnormality in the chest. 2. Mild thyromegaly. Correlate with thyroid function tests. 3. Incidental tiny left pulmonary nodule. If the patient has a history of smoking or other risk factors for lung cancer, a follow-uo chest CT may be obtained in 12 months. Otherwise, no further workup or surveillance is needed per guidelines. 1/2 FIBRINOGEN: 447 1/2 DDIMER: 0.31 1/2 FERRITIN: 250.1 1/2 LACTIC ACID: 0.87 1/2 TROPONIN I: 0.051 1/2 PROCALCITONIN: <0.05 1/2 SARS-COV-2 IGG Eval: 0.01 1/2 BNP: 23.8 1/2 SARS-CoV-2 (COVID-19): >2500.0 1/2 TROPONIN I: 0.047 1/3 FIBRINOGEN: 493 1/3 DDIMER: 0.34 ESR: 36 1/4 FIBRINOGEN: 463 1/4 DDIMER: 0.30 1/4 ESR: 30
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: C-reactive protein increased, COVID-19, Chest X-ray abnormal, Chest pain, Fibrin D dimer
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/25, Pfizer dose #1 04/15, Pfizer, dose #2 12/23, Pfizer, dose #3 1/1 COVID swab, result: detected 12/22 pt cc: exposure: unknown 1/1 pt admit Medicine cc: chest/neck/shoulder pain dx: chest pain, covid LOS: 3 days 1/1 TROPONIN I: 0.047 1/1 CRP: 1.621 1/1 CXR IMPRESSION: No pleural effusion or pneumothorax is identified. There is a 1.0 cm nodular density in the left lower lung which could reflect the patient's left nipple. Repeat study with nipple markers is recommended for confirmation to exclude a pulmonary lesion. Cardiomediastinal contours appear within normal limits. 1/2 CTA PE IMPRESSION: 1. No evidence of pulmonary embolism or other acute abnormality in the chest. 2. Mild thyromegaly. Correlate with thyroid function tests. 3. Incidental tiny left pulmonary nodule. If the patient has a history of smoking or other risk factors for lung cancer, a follow-uo chest CT may be obtained in 12 months. Otherwise, no further workup or surveillance is needed per guidelines. 1/2 FIBRINOGEN: 447 1/2 DDIMER: 0.31 1/2 FERRITIN: 250.1 1/2 LACTIC ACID: 0.87 1/2 TROPONIN I: 0.051 1/2 PROCALCITONIN: <0.05 1/2 SARS-COV-2 IGG Eval: 0.01 1/2 BNP: 23.8 1/2 SARS-CoV-2 (COVID-19): >2500.0 1/2 TROPONIN I: 0.047 1/3 FIBRINOGEN: 493 1/3 DDIMER: 0.34 ESR: 36 1/4 FIBRINOGEN: 463 1/4 DDIMER: 0.30 1/4 ESR: 30
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Goitre, Neck pain, Procalcitonin, Pulmonary mass, Red blood cell sedimentation rate increased
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/25, Pfizer dose #1 04/15, Pfizer, dose #2 12/23, Pfizer, dose #3 1/1 COVID swab, result: detected 12/22 pt cc: exposure: unknown 1/1 pt admit Medicine cc: chest/neck/shoulder pain dx: chest pain, covid LOS: 3 days 1/1 TROPONIN I: 0.047 1/1 CRP: 1.621 1/1 CXR IMPRESSION: No pleural effusion or pneumothorax is identified. There is a 1.0 cm nodular density in the left lower lung which could reflect the patient's left nipple. Repeat study with nipple markers is recommended for confirmation to exclude a pulmonary lesion. Cardiomediastinal contours appear within normal limits. 1/2 CTA PE IMPRESSION: 1. No evidence of pulmonary embolism or other acute abnormality in the chest. 2. Mild thyromegaly. Correlate with thyroid function tests. 3. Incidental tiny left pulmonary nodule. If the patient has a history of smoking or other risk factors for lung cancer, a follow-uo chest CT may be obtained in 12 months. Otherwise, no further workup or surveillance is needed per guidelines. 1/2 FIBRINOGEN: 447 1/2 DDIMER: 0.31 1/2 FERRITIN: 250.1 1/2 LACTIC ACID: 0.87 1/2 TROPONIN I: 0.051 1/2 PROCALCITONIN: <0.05 1/2 SARS-COV-2 IGG Eval: 0.01 1/2 BNP: 23.8 1/2 SARS-CoV-2 (COVID-19): >2500.0 1/2 TROPONIN I: 0.047 1/3 FIBRINOGEN: 493 1/3 DDIMER: 0.34 ESR: 36 1/4 FIBRINOGEN: 463 1/4 DDIMER: 0.30 1/4 ESR: 30
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 antibody test, SARS-CoV-2 test positive, Serum ferritin normal, Troponin I increased
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/25, Pfizer dose #1 04/15, Pfizer, dose #2 12/23, Pfizer, dose #3 1/1 COVID swab, result: detected 12/22 pt cc: exposure: unknown 1/1 pt admit Medicine cc: chest/neck/shoulder pain dx: chest pain, covid LOS: 3 days 1/1 TROPONIN I: 0.047 1/1 CRP: 1.621 1/1 CXR IMPRESSION: No pleural effusion or pneumothorax is identified. There is a 1.0 cm nodular density in the left lower lung which could reflect the patient's left nipple. Repeat study with nipple markers is recommended for confirmation to exclude a pulmonary lesion. Cardiomediastinal contours appear within normal limits. 1/2 CTA PE IMPRESSION: 1. No evidence of pulmonary embolism or other acute abnormality in the chest. 2. Mild thyromegaly. Correlate with thyroid function tests. 3. Incidental tiny left pulmonary nodule. If the patient has a history of smoking or other risk factors for lung cancer, a follow-uo chest CT may be obtained in 12 months. Otherwise, no further workup or surveillance is needed per guidelines. 1/2 FIBRINOGEN: 447 1/2 DDIMER: 0.31 1/2 FERRITIN: 250.1 1/2 LACTIC ACID: 0.87 1/2 TROPONIN I: 0.051 1/2 PROCALCITONIN: <0.05 1/2 SARS-COV-2 IGG Eval: 0.01 1/2 BNP: 23.8 1/2 SARS-CoV-2 (COVID-19): >2500.0 1/2 TROPONIN I: 0.047 1/3 FIBRINOGEN: 493 1/3 DDIMER: 0.34 ESR: 36 1/4 FIBRINOGEN: 463 1/4 DDIMER: 0.30 1/4 ESR: 30
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, COVID-19, Chest X-ray normal, Dyspnoea, Fibrin D dimer
Clinical narrative: Narrative: COVID infection following COVID vaccine series 07/28, Pfizer, dose #1 08/25, Pfizer, dose #2 12/29 COVID swab, result: detected 12/26 pt cc: low grade fevers, headache, body aches, sore throat, sinus congestion, cough productive of clear sputum, dyspnea; exposure: unknown; 12/29 Pt admit to ED cc: low grade fevers, headache, body aches, sore throat, sinus congestion, cough productive of clear sputum, dyspnea dx: COVID LOS: 1day 12/29 PT: 12.1 12/29 INR 1.08 12/29 DDIMER 0.53 12/29 TROPONIN 1: <0.016 12/29 CTA PE:. Negative study for pulmonary embolism. 2. No acute pulmonary disease. 3. Small to moderate-sized hiatal hernia. 12/29 CXR impression: No pleural effusion or pneumothorax. No pulmonary edema or focal consolidation. Normal cardiomediastinal silhouette.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Hiatus hernia, Inappropriate schedule of product administration, International normalised ratio normal, Oropharyngeal pain
Clinical narrative: Narrative: COVID infection following COVID vaccine series 07/28, Pfizer, dose #1 08/25, Pfizer, dose #2 12/29 COVID swab, result: detected 12/26 pt cc: low grade fevers, headache, body aches, sore throat, sinus congestion, cough productive of clear sputum, dyspnea; exposure: unknown; 12/29 Pt admit to ED cc: low grade fevers, headache, body aches, sore throat, sinus congestion, cough productive of clear sputum, dyspnea dx: COVID LOS: 1day 12/29 PT: 12.1 12/29 INR 1.08 12/29 DDIMER 0.53 12/29 TROPONIN 1: <0.016 12/29 CTA PE:. Negative study for pulmonary embolism. 2. No acute pulmonary disease. 3. Small to moderate-sized hiatal hernia. 12/29 CXR impression: No pleural effusion or pneumothorax. No pulmonary edema or focal consolidation. Normal cardiomediastinal silhouette.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Pain, Productive cough, Prothrombin time normal, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 07/28, Pfizer, dose #1 08/25, Pfizer, dose #2 12/29 COVID swab, result: detected 12/26 pt cc: low grade fevers, headache, body aches, sore throat, sinus congestion, cough productive of clear sputum, dyspnea; exposure: unknown; 12/29 Pt admit to ED cc: low grade fevers, headache, body aches, sore throat, sinus congestion, cough productive of clear sputum, dyspnea dx: COVID LOS: 1day 12/29 PT: 12.1 12/29 INR 1.08 12/29 DDIMER 0.53 12/29 TROPONIN 1: <0.016 12/29 CTA PE:. Negative study for pulmonary embolism. 2. No acute pulmonary disease. 3. Small to moderate-sized hiatal hernia. 12/29 CXR impression: No pleural effusion or pneumothorax. No pulmonary edema or focal consolidation. Normal cardiomediastinal silhouette.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Sinus congestion, Troponin I normal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 07/28, Pfizer, dose #1 08/25, Pfizer, dose #2 12/29 COVID swab, result: detected 12/26 pt cc: low grade fevers, headache, body aches, sore throat, sinus congestion, cough productive of clear sputum, dyspnea; exposure: unknown; 12/29 Pt admit to ED cc: low grade fevers, headache, body aches, sore throat, sinus congestion, cough productive of clear sputum, dyspnea dx: COVID LOS: 1day 12/29 PT: 12.1 12/29 INR 1.08 12/29 DDIMER 0.53 12/29 TROPONIN 1: <0.016 12/29 CTA PE:. Negative study for pulmonary embolism. 2. No acute pulmonary disease. 3. Small to moderate-sized hiatal hernia. 12/29 CXR impression: No pleural effusion or pneumothorax. No pulmonary edema or focal consolidation. Normal cardiomediastinal silhouette.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chest X-ray normal, Cough, Red blood cell sedimentation rate, Rhinorrhoea
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 02/23, Pfizer dose #1 03/16, Pfizer, dose #2 09/02, Pfizer, dose #3 12/30 COVID swab, result detected 1/10 COVID swab, result: detected 12/27 pt cc: cough, rhinorrhea, exposure: unknown 1/10 TROPONIN I: <0.016 1/10 ESR: 20 1/10 CXR IMPRESSION: No acute abnormality.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Troponin
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 02/23, Pfizer dose #1 03/16, Pfizer, dose #2 09/02, Pfizer, dose #3 12/30 COVID swab, result detected 1/10 COVID swab, result: detected 12/27 pt cc: cough, rhinorrhea, exposure: unknown 1/10 TROPONIN I: <0.016 1/10 ESR: 20 1/10 CXR IMPRESSION: No acute abnormality.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Cough, Oropharyngeal pain, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 03/03, Pfizer, dose #1 03/24, Pfizer, dose #2 COVID swab, result: detected 12/28 pt cc: sore throat, cough exposure: unknown 12/31 pt admit to ED cc: sore throat, cough dx: Covid illness LOS: 1 day
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Chest X-ray normal, Cough, Respiratory tract congestion
Clinical narrative: Narrative: COVID infection following COVID vaccine series 02/04, Pfizer dose #1 02/25, Pfizer, dose #2 1/10, Pfizer, dose #2 12/28 COVID swab, result: detected 12/20 COVID swab, result: not detected 12/30 COVID swab, result: detected 1/5 COVID swab, result: detected 12/27 pt cc: cough/congestion and weakness exposure: unknown 12/30 pt admit ED cc: cough/congestion and weakness dx: COVID LOS: 1 day 12/30 CXR impression: No acute abnormality.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 02/04, Pfizer dose #1 02/25, Pfizer, dose #2 1/10, Pfizer, dose #2 12/28 COVID swab, result: detected 12/20 COVID swab, result: not detected 12/30 COVID swab, result: detected 1/5 COVID swab, result: detected 12/27 pt cc: cough/congestion and weakness exposure: unknown 12/30 pt admit ED cc: cough/congestion and weakness dx: COVID LOS: 1 day 12/30 CXR impression: No acute abnormality.
Age: 56.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Dyspnoea
Clinical narrative: Narrative: 55 year old male admitted on 1/24/22 with SOB and treatment of COVID-19 infection. He had been vaccinated x 2 with Moderna (1st dose: 4/7/21, 2nd dose 5/5/21). He received 5 days of remdesivir and 4 days of IV  dexamethasone for treatment and was discharged on 1/28/22.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Narrative:  1st Moderna COVID Vaccine: 9/2/2021 2nd Monderna COVID Vaccine: 9/30/2021 Tested positive for COVID: 12/17/2021 received one treatment of Etesevimab & Bamlanivimab 12/20/21 patient admitted for impatient stay 12/22/21 - 12/23/2021
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Acquired diaphragmatic eventration, Activated partial thromboplastin time shortened, Acute respiratory failure, Angiogram pulmonary abnormal, Blood bicarbonate normal
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/08, Moderna , dose #1 07/12, Jansen , dose #2 12/30 COVID swab, result: detected 08/03 pt cc: cough/congestion/fever/SOB: +COVID contact at home 1/2/2022 pt admit Medicine cc: cough/congestion/fever/sob dx: Acute hypoxic respiratory failure due to COVID PNA LOS: 7 days 1/02 CXR IMPRESSION: Extensive increased patchy opacities are present throughout both Lungs. No pleural effusion or pneumothorax is identified. Cardiac silhouette appears stable. There is slight elevation of the left hemidiaphragm. 1/02 CTA PE: 1. No evidence for pulmonary embolism. 2. Severe diffuse groundglass opacities in the bilateral lungs with additional tree-in-bud nodular densities in the lung bases. Findings are likely related to COVID pneumonia given history. Consider follow-up imaging after treatment completion to ensure resolution. 3. Enlarged mediastinal and hilar lymph nodes, which may be reactive. Attention on follow-up. 1/02PT/APTT/INR: 14.2/29.6/1.27 1/02 BNP: 246 1/02 ABG: i-pH: 7.42, i=PCO2: 34.7, iPO2: 43, i-HCO3L 22.5 1/02 FIBRINOGEN:>1000 1/02 DDIMER: 1.65 1/02 LACTIC ACID: 1.39 1/02 PROCALCITONIN: 13.46 1/03 ESR: 106 1/09 PROCALCITONIN: 0.09 1/09 FIBRINOGEN: 277 1/09 DDIMER: 3.01 1/10 PROCALCITONIN: 0.06 1/10 FIBRINOGEN: 243 1/10 DDIMER: 3.21 1/11 FIBRINOGEN: 271 1/11 DDIMER: 2.20 1/11 FIBRINOGEN: 222 1/11 DDIMER:3042 1/11 ESR: 15 1
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Blood fibrinogen increased, Blood gases abnormal, Blood lactic acid, Blood pH normal, Brain natriuretic peptide increased
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/08, Moderna , dose #1 07/12, Jansen , dose #2 12/30 COVID swab, result: detected 08/03 pt cc: cough/congestion/fever/SOB: +COVID contact at home 1/2/2022 pt admit Medicine cc: cough/congestion/fever/sob dx: Acute hypoxic respiratory failure due to COVID PNA LOS: 7 days 1/02 CXR IMPRESSION: Extensive increased patchy opacities are present throughout both Lungs. No pleural effusion or pneumothorax is identified. Cardiac silhouette appears stable. There is slight elevation of the left hemidiaphragm. 1/02 CTA PE: 1. No evidence for pulmonary embolism. 2. Severe diffuse groundglass opacities in the bilateral lungs with additional tree-in-bud nodular densities in the lung bases. Findings are likely related to COVID pneumonia given history. Consider follow-up imaging after treatment completion to ensure resolution. 3. Enlarged mediastinal and hilar lymph nodes, which may be reactive. Attention on follow-up. 1/02PT/APTT/INR: 14.2/29.6/1.27 1/02 BNP: 246 1/02 ABG: i-pH: 7.42, i=PCO2: 34.7, iPO2: 43, i-HCO3L 22.5 1/02 FIBRINOGEN:>1000 1/02 DDIMER: 1.65 1/02 LACTIC ACID: 1.39 1/02 PROCALCITONIN: 13.46 1/03 ESR: 106 1/09 PROCALCITONIN: 0.09 1/09 FIBRINOGEN: 277 1/09 DDIMER: 3.01 1/10 PROCALCITONIN: 0.06 1/10 FIBRINOGEN: 243 1/10 DDIMER: 3.21 1/11 FIBRINOGEN: 271 1/11 DDIMER: 2.20 1/11 FIBRINOGEN: 222 1/11 DDIMER:3042 1/11 ESR: 15 1
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Chest X-ray abnormal, Cough, Dyspnoea
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/08, Moderna , dose #1 07/12, Jansen , dose #2 12/30 COVID swab, result: detected 08/03 pt cc: cough/congestion/fever/SOB: +COVID contact at home 1/2/2022 pt admit Medicine cc: cough/congestion/fever/sob dx: Acute hypoxic respiratory failure due to COVID PNA LOS: 7 days 1/02 CXR IMPRESSION: Extensive increased patchy opacities are present throughout both Lungs. No pleural effusion or pneumothorax is identified. Cardiac silhouette appears stable. There is slight elevation of the left hemidiaphragm. 1/02 CTA PE: 1. No evidence for pulmonary embolism. 2. Severe diffuse groundglass opacities in the bilateral lungs with additional tree-in-bud nodular densities in the lung bases. Findings are likely related to COVID pneumonia given history. Consider follow-up imaging after treatment completion to ensure resolution. 3. Enlarged mediastinal and hilar lymph nodes, which may be reactive. Attention on follow-up. 1/02PT/APTT/INR: 14.2/29.6/1.27 1/02 BNP: 246 1/02 ABG: i-pH: 7.42, i=PCO2: 34.7, iPO2: 43, i-HCO3L 22.5 1/02 FIBRINOGEN:>1000 1/02 DDIMER: 1.65 1/02 LACTIC ACID: 1.39 1/02 PROCALCITONIN: 13.46 1/03 ESR: 106 1/09 PROCALCITONIN: 0.09 1/09 FIBRINOGEN: 277 1/09 DDIMER: 3.01 1/10 PROCALCITONIN: 0.06 1/10 FIBRINOGEN: 243 1/10 DDIMER: 3.21 1/11 FIBRINOGEN: 271 1/11 DDIMER: 2.20 1/11 FIBRINOGEN: 222 1/11 DDIMER:3042 1/11 ESR: 15 1
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Exposure to SARS-CoV-2, Exposure via direct contact, Fibrin D dimer, Hilar lymphadenopathy, Interchange of vaccine products
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/08, Moderna , dose #1 07/12, Jansen , dose #2 12/30 COVID swab, result: detected 08/03 pt cc: cough/congestion/fever/SOB: +COVID contact at home 1/2/2022 pt admit Medicine cc: cough/congestion/fever/sob dx: Acute hypoxic respiratory failure due to COVID PNA LOS: 7 days 1/02 CXR IMPRESSION: Extensive increased patchy opacities are present throughout both Lungs. No pleural effusion or pneumothorax is identified. Cardiac silhouette appears stable. There is slight elevation of the left hemidiaphragm. 1/02 CTA PE: 1. No evidence for pulmonary embolism. 2. Severe diffuse groundglass opacities in the bilateral lungs with additional tree-in-bud nodular densities in the lung bases. Findings are likely related to COVID pneumonia given history. Consider follow-up imaging after treatment completion to ensure resolution. 3. Enlarged mediastinal and hilar lymph nodes, which may be reactive. Attention on follow-up. 1/02PT/APTT/INR: 14.2/29.6/1.27 1/02 BNP: 246 1/02 ABG: i-pH: 7.42, i=PCO2: 34.7, iPO2: 43, i-HCO3L 22.5 1/02 FIBRINOGEN:>1000 1/02 DDIMER: 1.65 1/02 LACTIC ACID: 1.39 1/02 PROCALCITONIN: 13.46 1/03 ESR: 106 1/09 PROCALCITONIN: 0.09 1/09 FIBRINOGEN: 277 1/09 DDIMER: 3.01 1/10 PROCALCITONIN: 0.06 1/10 FIBRINOGEN: 243 1/10 DDIMER: 3.21 1/11 FIBRINOGEN: 271 1/11 DDIMER: 2.20 1/11 FIBRINOGEN: 222 1/11 DDIMER:3042 1/11 ESR: 15 1
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: International normalised ratio increased, Lung opacity, Lymphadenopathy mediastinal, PCO2 decreased, PO2 decreased
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/08, Moderna , dose #1 07/12, Jansen , dose #2 12/30 COVID swab, result: detected 08/03 pt cc: cough/congestion/fever/SOB: +COVID contact at home 1/2/2022 pt admit Medicine cc: cough/congestion/fever/sob dx: Acute hypoxic respiratory failure due to COVID PNA LOS: 7 days 1/02 CXR IMPRESSION: Extensive increased patchy opacities are present throughout both Lungs. No pleural effusion or pneumothorax is identified. Cardiac silhouette appears stable. There is slight elevation of the left hemidiaphragm. 1/02 CTA PE: 1. No evidence for pulmonary embolism. 2. Severe diffuse groundglass opacities in the bilateral lungs with additional tree-in-bud nodular densities in the lung bases. Findings are likely related to COVID pneumonia given history. Consider follow-up imaging after treatment completion to ensure resolution. 3. Enlarged mediastinal and hilar lymph nodes, which may be reactive. Attention on follow-up. 1/02PT/APTT/INR: 14.2/29.6/1.27 1/02 BNP: 246 1/02 ABG: i-pH: 7.42, i=PCO2: 34.7, iPO2: 43, i-HCO3L 22.5 1/02 FIBRINOGEN:>1000 1/02 DDIMER: 1.65 1/02 LACTIC ACID: 1.39 1/02 PROCALCITONIN: 13.46 1/03 ESR: 106 1/09 PROCALCITONIN: 0.09 1/09 FIBRINOGEN: 277 1/09 DDIMER: 3.01 1/10 PROCALCITONIN: 0.06 1/10 FIBRINOGEN: 243 1/10 DDIMER: 3.21 1/11 FIBRINOGEN: 271 1/11 DDIMER: 2.20 1/11 FIBRINOGEN: 222 1/11 DDIMER:3042 1/11 ESR: 15 1
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Procalcitonin, Prothrombin time prolonged, Pulmonary mass, Pyrexia, Red blood cell sedimentation rate increased
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/08, Moderna , dose #1 07/12, Jansen , dose #2 12/30 COVID swab, result: detected 08/03 pt cc: cough/congestion/fever/SOB: +COVID contact at home 1/2/2022 pt admit Medicine cc: cough/congestion/fever/sob dx: Acute hypoxic respiratory failure due to COVID PNA LOS: 7 days 1/02 CXR IMPRESSION: Extensive increased patchy opacities are present throughout both Lungs. No pleural effusion or pneumothorax is identified. Cardiac silhouette appears stable. There is slight elevation of the left hemidiaphragm. 1/02 CTA PE: 1. No evidence for pulmonary embolism. 2. Severe diffuse groundglass opacities in the bilateral lungs with additional tree-in-bud nodular densities in the lung bases. Findings are likely related to COVID pneumonia given history. Consider follow-up imaging after treatment completion to ensure resolution. 3. Enlarged mediastinal and hilar lymph nodes, which may be reactive. Attention on follow-up. 1/02PT/APTT/INR: 14.2/29.6/1.27 1/02 BNP: 246 1/02 ABG: i-pH: 7.42, i=PCO2: 34.7, iPO2: 43, i-HCO3L 22.5 1/02 FIBRINOGEN:>1000 1/02 DDIMER: 1.65 1/02 LACTIC ACID: 1.39 1/02 PROCALCITONIN: 13.46 1/03 ESR: 106 1/09 PROCALCITONIN: 0.09 1/09 FIBRINOGEN: 277 1/09 DDIMER: 3.01 1/10 PROCALCITONIN: 0.06 1/10 FIBRINOGEN: 243 1/10 DDIMER: 3.21 1/11 FIBRINOGEN: 271 1/11 DDIMER: 2.20 1/11 FIBRINOGEN: 222 1/11 DDIMER:3042 1/11 ESR: 15 1
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/08, Moderna , dose #1 07/12, Jansen , dose #2 12/30 COVID swab, result: detected 08/03 pt cc: cough/congestion/fever/SOB: +COVID contact at home 1/2/2022 pt admit Medicine cc: cough/congestion/fever/sob dx: Acute hypoxic respiratory failure due to COVID PNA LOS: 7 days 1/02 CXR IMPRESSION: Extensive increased patchy opacities are present throughout both Lungs. No pleural effusion or pneumothorax is identified. Cardiac silhouette appears stable. There is slight elevation of the left hemidiaphragm. 1/02 CTA PE: 1. No evidence for pulmonary embolism. 2. Severe diffuse groundglass opacities in the bilateral lungs with additional tree-in-bud nodular densities in the lung bases. Findings are likely related to COVID pneumonia given history. Consider follow-up imaging after treatment completion to ensure resolution. 3. Enlarged mediastinal and hilar lymph nodes, which may be reactive. Attention on follow-up. 1/02PT/APTT/INR: 14.2/29.6/1.27 1/02 BNP: 246 1/02 ABG: i-pH: 7.42, i=PCO2: 34.7, iPO2: 43, i-HCO3L 22.5 1/02 FIBRINOGEN:>1000 1/02 DDIMER: 1.65 1/02 LACTIC ACID: 1.39 1/02 PROCALCITONIN: 13.46 1/03 ESR: 106 1/09 PROCALCITONIN: 0.09 1/09 FIBRINOGEN: 277 1/09 DDIMER: 3.01 1/10 PROCALCITONIN: 0.06 1/10 FIBRINOGEN: 243 1/10 DDIMER: 3.21 1/11 FIBRINOGEN: 271 1/11 DDIMER: 2.20 1/11 FIBRINOGEN: 222 1/11 DDIMER:3042 1/11 ESR: 15 1
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, Arteriosclerosis, Asthenia, COVID-19, COVID-19 pneumonia
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/30, Pfizer, dose #1 (hospital) 02/27, Pfizer, dose 2 (hospital) 1/1 COVID swab, result: detected 1/1 pt admit Medicine cc: "flu like illness" syx x 9 days with cough, shortness of breath, congestion, body aches generalized weakness: dx: COVID PNA LOS: 5 days 1/1 CXR IMPRESSION: Sternal retention wires in place. Intracardiac device is present consistent with reported history of prior surgical clipping of left atrial appendage and mitral valvuloplasty. Increased parenchymal markings left lung base. Presumed mild infiltrate. No other focal alveolar infiltrate/consolidation. No pleural effusion or pneumothorax. No congestive failure. Atherosclerotic vascular calcifications are coarse. No aneurysm. No mass lesions. No other acute findings. 1/2 CTA PE IMPRESSION: Consolidation in the left lower lobe and multiple additional multifocal patchy groundglass opacities in both lungs most compatible with an infectious/inflammatory process including atypicals such as COVID-19 pneumonia. No pulmonary emoblism. 12/23 pt CC: cough, shortness of breath, congestion, body aches generalized weakness exposure: unknown 1/5 CXR IMPRESSION: Pneumonic infiltrates, most obvious in the left lung, mildly increased since earlier chest x-ray. 1/13 clinically resolved
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Chest X-ray abnormal, Cough, Dyspnoea, Inappropriate schedule of product administration, Influenza like illness
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/30, Pfizer, dose #1 (hospital) 02/27, Pfizer, dose 2 (hospital) 1/1 COVID swab, result: detected 1/1 pt admit Medicine cc: "flu like illness" syx x 9 days with cough, shortness of breath, congestion, body aches generalized weakness: dx: COVID PNA LOS: 5 days 1/1 CXR IMPRESSION: Sternal retention wires in place. Intracardiac device is present consistent with reported history of prior surgical clipping of left atrial appendage and mitral valvuloplasty. Increased parenchymal markings left lung base. Presumed mild infiltrate. No other focal alveolar infiltrate/consolidation. No pleural effusion or pneumothorax. No congestive failure. Atherosclerotic vascular calcifications are coarse. No aneurysm. No mass lesions. No other acute findings. 1/2 CTA PE IMPRESSION: Consolidation in the left lower lobe and multiple additional multifocal patchy groundglass opacities in both lungs most compatible with an infectious/inflammatory process including atypicals such as COVID-19 pneumonia. No pulmonary emoblism. 12/23 pt CC: cough, shortness of breath, congestion, body aches generalized weakness exposure: unknown 1/5 CXR IMPRESSION: Pneumonic infiltrates, most obvious in the left lung, mildly increased since earlier chest x-ray. 1/13 clinically resolved
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Lung consolidation, Lung infiltration, Lung opacity, Malaise, Pain
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/30, Pfizer, dose #1 (hospital) 02/27, Pfizer, dose 2 (hospital) 1/1 COVID swab, result: detected 1/1 pt admit Medicine cc: "flu like illness" syx x 9 days with cough, shortness of breath, congestion, body aches generalized weakness: dx: COVID PNA LOS: 5 days 1/1 CXR IMPRESSION: Sternal retention wires in place. Intracardiac device is present consistent with reported history of prior surgical clipping of left atrial appendage and mitral valvuloplasty. Increased parenchymal markings left lung base. Presumed mild infiltrate. No other focal alveolar infiltrate/consolidation. No pleural effusion or pneumothorax. No congestive failure. Atherosclerotic vascular calcifications are coarse. No aneurysm. No mass lesions. No other acute findings. 1/2 CTA PE IMPRESSION: Consolidation in the left lower lobe and multiple additional multifocal patchy groundglass opacities in both lungs most compatible with an infectious/inflammatory process including atypicals such as COVID-19 pneumonia. No pulmonary emoblism. 12/23 pt CC: cough, shortness of breath, congestion, body aches generalized weakness exposure: unknown 1/5 CXR IMPRESSION: Pneumonic infiltrates, most obvious in the left lung, mildly increased since earlier chest x-ray. 1/13 clinically resolved
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Pneumonia, Pneumonitis, Respiratory tract congestion, SARS-CoV-2 test positive, Vascular calcification
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/30, Pfizer, dose #1 (hospital) 02/27, Pfizer, dose 2 (hospital) 1/1 COVID swab, result: detected 1/1 pt admit Medicine cc: "flu like illness" syx x 9 days with cough, shortness of breath, congestion, body aches generalized weakness: dx: COVID PNA LOS: 5 days 1/1 CXR IMPRESSION: Sternal retention wires in place. Intracardiac device is present consistent with reported history of prior surgical clipping of left atrial appendage and mitral valvuloplasty. Increased parenchymal markings left lung base. Presumed mild infiltrate. No other focal alveolar infiltrate/consolidation. No pleural effusion or pneumothorax. No congestive failure. Atherosclerotic vascular calcifications are coarse. No aneurysm. No mass lesions. No other acute findings. 1/2 CTA PE IMPRESSION: Consolidation in the left lower lobe and multiple additional multifocal patchy groundglass opacities in both lungs most compatible with an infectious/inflammatory process including atypicals such as COVID-19 pneumonia. No pulmonary emoblism. 12/23 pt CC: cough, shortness of breath, congestion, body aches generalized weakness exposure: unknown 1/5 CXR IMPRESSION: Pneumonic infiltrates, most obvious in the left lung, mildly increased since earlier chest x-ray. 1/13 clinically resolved
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Cough, Myalgia, Pain, Pyrexia
Clinical narrative: Narrative: COVID infection following COVID vaccine series 08/16, Pfizer, dose #1 09/07, Pfizer, dose #2 1/1 COVID swab, result: detected 1/1 pt cc: fever, myalgias exposure: unknown 1/1 pt admit to ED cc: cough/congestion/body aches dx: Coronavirus LOS: 1 day 1/1 TROPONIN I: <0.016
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory tract congestion, SARS-CoV-2 test positive, Troponin I normal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 08/16, Pfizer, dose #1 09/07, Pfizer, dose #2 1/1 COVID swab, result: detected 1/1 pt cc: fever, myalgias exposure: unknown 1/1 pt admit to ED cc: cough/congestion/body aches dx: Coronavirus LOS: 1 day 1/1 TROPONIN I: <0.016
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, COVID-19, Chest X-ray abnormal, Cough
Clinical narrative: Narrative: COVID infection following COVID vaccine series 10/7, Pfizer, dose #1 10/21, Pfizer, dose #2 12/30 COVID swab, result: detected 1/7 COVID swab,  result: detected 11/15 CXR IMPRESSION:  Pulmonary vascular crowding due to the expiratory technique. 12/29 pt cc: fatigue, cough, loss of taste or smell,  myalgias, rhinorrhea, sore throat exposure: unknown
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Myalgia, Oropharyngeal pain, Pulmonary vascular disorder, Rhinorrhoea
Clinical narrative: Narrative: COVID infection following COVID vaccine series 10/7, Pfizer, dose #1 10/21, Pfizer, dose #2 12/30 COVID swab, result: detected 1/7 COVID swab,  result: detected 11/15 CXR IMPRESSION:  Pulmonary vascular crowding due to the expiratory technique. 12/29 pt cc: fatigue, cough, loss of taste or smell,  myalgias, rhinorrhea, sore throat exposure: unknown
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 10/7, Pfizer, dose #1 10/21, Pfizer, dose #2 12/30 COVID swab, result: detected 1/7 COVID swab,  result: detected 11/15 CXR IMPRESSION:  Pulmonary vascular crowding due to the expiratory technique. 12/29 pt cc: fatigue, cough, loss of taste or smell,  myalgias, rhinorrhea, sore throat exposure: unknown
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, Atrial fibrillation, Blood fibrinogen normal, Blood lactic acid, Brain natriuretic peptide increased
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/02. Pfizer dose #1 04/23, Pfizer, dose #2 1/1 COVID swab, result: detected 12/21 pt cc: cough, exposure: unknown 1/1 pt admit Medicine cc: SOB, CP dx: Covid Pneumonia AFIB RVR LOS: 4 days 12/31 COVID swab, result: detected 1/1 CTA PE IMPRESSION: 1. No acute pulmonary emboli. 2. Findings of mild pulmonary edema. Superimposed infectious/inflammatory process possible. 1/1 CXR IMPRESSION: No evidence of acute cardiopulmonary abnormality. 1/1 TROPONIN I: 0.023 1/1 BNP: 129.8 1/1 TROPONIN I: 0.025 1/2 FIBRINOGEN: 352 1/2 FERRITIN: 150.7 1/2 SARS COV-2 IGG: 0.21 1/2 PROCALCITONIN: <0.05 1/2 DDIMER: 0.48 1/2 BNP 282.7 1/2 SARS-CoV-2 (COVID-19): 833.1 1/2 LACTIC ACID: 0.84 1/2 FIBRINOGEN: 336 1/2 DDIMER: 0.38 1/2 ESR: 26 1/3 FIBRINOGEN: 436 1/3 DDIMER: 0.47 1/3 ESR: 39 1/4 FIBRINOGEN: 311 1/4 DDIMER: 0.36 1/4 ESR: 23 1/5 FIBRINOGEN: 280 1/5 DDIMER: 0.42 1/5 ESR: 22 1/6 clinically resolved 1/10 COVID swab, result: detected
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Chest X-ray normal, Chest pain, Cough
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/02. Pfizer dose #1 04/23, Pfizer, dose #2 1/1 COVID swab, result: detected 12/21 pt cc: cough, exposure: unknown 1/1 pt admit Medicine cc: SOB, CP dx: Covid Pneumonia AFIB RVR LOS: 4 days 12/31 COVID swab, result: detected 1/1 CTA PE IMPRESSION: 1. No acute pulmonary emboli. 2. Findings of mild pulmonary edema. Superimposed infectious/inflammatory process possible. 1/1 CXR IMPRESSION: No evidence of acute cardiopulmonary abnormality. 1/1 TROPONIN I: 0.023 1/1 BNP: 129.8 1/1 TROPONIN I: 0.025 1/2 FIBRINOGEN: 352 1/2 FERRITIN: 150.7 1/2 SARS COV-2 IGG: 0.21 1/2 PROCALCITONIN: <0.05 1/2 DDIMER: 0.48 1/2 BNP 282.7 1/2 SARS-CoV-2 (COVID-19): 833.1 1/2 LACTIC ACID: 0.84 1/2 FIBRINOGEN: 336 1/2 DDIMER: 0.38 1/2 ESR: 26 1/3 FIBRINOGEN: 436 1/3 DDIMER: 0.47 1/3 ESR: 39 1/4 FIBRINOGEN: 311 1/4 DDIMER: 0.36 1/4 ESR: 23 1/5 FIBRINOGEN: 280 1/5 DDIMER: 0.42 1/5 ESR: 22 1/6 clinically resolved 1/10 COVID swab, result: detected
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Fibrin D dimer, Procalcitonin, Pulmonary oedema, Red blood cell sedimentation rate increased
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/02. Pfizer dose #1 04/23, Pfizer, dose #2 1/1 COVID swab, result: detected 12/21 pt cc: cough, exposure: unknown 1/1 pt admit Medicine cc: SOB, CP dx: Covid Pneumonia AFIB RVR LOS: 4 days 12/31 COVID swab, result: detected 1/1 CTA PE IMPRESSION: 1. No acute pulmonary emboli. 2. Findings of mild pulmonary edema. Superimposed infectious/inflammatory process possible. 1/1 CXR IMPRESSION: No evidence of acute cardiopulmonary abnormality. 1/1 TROPONIN I: 0.023 1/1 BNP: 129.8 1/1 TROPONIN I: 0.025 1/2 FIBRINOGEN: 352 1/2 FERRITIN: 150.7 1/2 SARS COV-2 IGG: 0.21 1/2 PROCALCITONIN: <0.05 1/2 DDIMER: 0.48 1/2 BNP 282.7 1/2 SARS-CoV-2 (COVID-19): 833.1 1/2 LACTIC ACID: 0.84 1/2 FIBRINOGEN: 336 1/2 DDIMER: 0.38 1/2 ESR: 26 1/3 FIBRINOGEN: 436 1/3 DDIMER: 0.47 1/3 ESR: 39 1/4 FIBRINOGEN: 311 1/4 DDIMER: 0.36 1/4 ESR: 23 1/5 FIBRINOGEN: 280 1/5 DDIMER: 0.42 1/5 ESR: 22 1/6 clinically resolved 1/10 COVID swab, result: detected
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 antibody test, SARS-CoV-2 test positive, Serum ferritin normal, Troponin I normal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/02. Pfizer dose #1 04/23, Pfizer, dose #2 1/1 COVID swab, result: detected 12/21 pt cc: cough, exposure: unknown 1/1 pt admit Medicine cc: SOB, CP dx: Covid Pneumonia AFIB RVR LOS: 4 days 12/31 COVID swab, result: detected 1/1 CTA PE IMPRESSION: 1. No acute pulmonary emboli. 2. Findings of mild pulmonary edema. Superimposed infectious/inflammatory process possible. 1/1 CXR IMPRESSION: No evidence of acute cardiopulmonary abnormality. 1/1 TROPONIN I: 0.023 1/1 BNP: 129.8 1/1 TROPONIN I: 0.025 1/2 FIBRINOGEN: 352 1/2 FERRITIN: 150.7 1/2 SARS COV-2 IGG: 0.21 1/2 PROCALCITONIN: <0.05 1/2 DDIMER: 0.48 1/2 BNP 282.7 1/2 SARS-CoV-2 (COVID-19): 833.1 1/2 LACTIC ACID: 0.84 1/2 FIBRINOGEN: 336 1/2 DDIMER: 0.38 1/2 ESR: 26 1/3 FIBRINOGEN: 436 1/3 DDIMER: 0.47 1/3 ESR: 39 1/4 FIBRINOGEN: 311 1/4 DDIMER: 0.36 1/4 ESR: 23 1/5 FIBRINOGEN: 280 1/5 DDIMER: 0.42 1/5 ESR: 22 1/6 clinically resolved 1/10 COVID swab, result: detected
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chest X-ray normal, Chills, Cough, Diarrhoea
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/01, Pfizer, dose #1 04/22, Pfizer, dose #2 1/3 COVID swab, result: detected 12/23 pt cc: chills, cough, diarrhea, fever, headache, myalgias, rhinorrhea exposure: unknown 01/03 pt admit to ED cc: sore throat and a nonproductive cough dx: COVID-19 LOS: 1 day 01/33 CXR impression: No acute cardiopulmonary disease.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Oropharyngeal pain, Pyrexia, Rhinorrhoea
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/01, Pfizer, dose #1 04/22, Pfizer, dose #2 1/3 COVID swab, result: detected 12/23 pt cc: chills, cough, diarrhea, fever, headache, myalgias, rhinorrhea exposure: unknown 01/03 pt admit to ED cc: sore throat and a nonproductive cough dx: COVID-19 LOS: 1 day 01/33 CXR impression: No acute cardiopulmonary disease.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/01, Pfizer, dose #1 04/22, Pfizer, dose #2 1/3 COVID swab, result: detected 12/23 pt cc: chills, cough, diarrhea, fever, headache, myalgias, rhinorrhea exposure: unknown 01/03 pt admit to ED cc: sore throat and a nonproductive cough dx: COVID-19 LOS: 1 day 01/33 CXR impression: No acute cardiopulmonary disease.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chest X-ray abnormal, Cor pulmonale acute, Cough, Dyspnoea
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/26, Pfizer, dose #1 02/17, Pfizer, dose #2 09/13, Pfizer, dose #3 1/1 COVID swab, result: detected 12/18 pt cc: headache, cough, shortness of breath exposure: unknown 1/1 pt admit to ED cc: dx COVID19, LOS: 1 day 1/1 CXR impression: acute cardiopulmonary disease. 1/3 clinically resolved
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Inappropriate schedule of product administration, SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/26, Pfizer, dose #1 02/17, Pfizer, dose #2 09/13, Pfizer, dose #3 1/1 COVID swab, result: detected 12/18 pt cc: headache, cough, shortness of breath exposure: unknown 1/1 pt admit to ED cc: dx COVID19, LOS: 1 day 1/1 CXR impression: acute cardiopulmonary disease. 1/3 clinically resolved
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Cough, SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/04, Pfizer, dose #1 01/25, Pfizer, dose #2 01/03 COVID swab, result: detected 01/03 pt cc: cough, exposure: unknown 01/03 pt admit to ED cc: cough dx: COVID+ LOS 1 day
Age: 78.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Atelectasis, Atypical pneumonia, COVID-19, Chest X-ray abnormal, Chills
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/13, Pfizer, dose #1 02/03, Pfizer, dose #2, Pfizer, dose #3 pt cc: exposure: unknown 01/03 pt admit to ED cc: COUGH/CONGESTION/DECREASED/DECREASED APPETITE, CHILS AND MILD HEADACHE dx: COVID-19 INFECTION, ATYPICAL PNEUMONIA LOS: 1 day 01/03 CXR impression: Bibasilar brochovascular crowding and atelectasis with no discrete focal airspace consolidation.
Age: 78.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cough, Decreased appetite, Headache, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/13, Pfizer, dose #1 02/03, Pfizer, dose #2, Pfizer, dose #3 pt cc: exposure: unknown 01/03 pt admit to ED cc: COUGH/CONGESTION/DECREASED/DECREASED APPETITE, CHILS AND MILD HEADACHE dx: COVID-19 INFECTION, ATYPICAL PNEUMONIA LOS: 1 day 01/03 CXR impression: Bibasilar brochovascular crowding and atelectasis with no discrete focal airspace consolidation.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Cough, Death, Oropharyngeal pain, Rhinorrhoea
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/22, SINOVAC, dose #1 (NON FACILITY) 05/20, SINOVAC, dose #2(NON VACILITY) 01/02 COVID swab, result: detected 01/03 COVID sab, result: detected 01/02 pt cc: mild cough, Rhinorrhea, and sore throat exposure: unknown 01/03 pt admit ED cc: mild cough, Rhinorrhea and sore throat dx: COVID+ LOS: 1 day  01/30/2021 date of death 1/30/2022
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/22, SINOVAC, dose #1 (NON FACILITY) 05/20, SINOVAC, dose #2(NON VACILITY) 01/02 COVID swab, result: detected 01/03 COVID sab, result: detected 01/02 pt cc: mild cough, Rhinorrhea, and sore throat exposure: unknown 01/03 pt admit ED cc: mild cough, Rhinorrhea and sore throat dx: COVID+ LOS: 1 day  01/30/2021 date of death 1/30/2022
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Blood bicarbonate, Blood pH normal, C-reactive protein increased, COVID-19, Chest X-ray abnormal
Clinical narrative: Narrative: COVID infection following COVID vaccine series and after previous COVID infection 07/25, Pfizer, dose #1 (FACILITY) 08/15, Pfizer, dose # 2 (FACILITY) 07/28 COVID swab, result: detected 12/23 COVID swab, result: detected 08/05 ABG: i-pH 7.44, i-PCO2, iPO2 39.0, i-PO2 71, i-HCO2 26.8 08/05 ddimer: 0.26 08/05 CRP: 5.582 08/05 PROCALCITONIN: <0.05 08/05 CXR IMPRESSION: Faint groundglass opacities involving the bilateral lower lobes and left upper lobe. Finding may be consistent with the patient's known positive COVID status. If further characterization is desired, consider chest CT. 08/07 ESR: 57 08/07 FIBRINOGEN: 449 08/07 DDIMER: 0.79 08/05 pt cc: exposure: unknown 08/05 pt admit Medicine cc: Cough, shortness of breath dx: hypoxemia, COVID 19 LOS: 1 day
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Fibrin D dimer normal, Lung opacity, PCO2, PO2 decreased, Procalcitonin
Clinical narrative: Narrative: COVID infection following COVID vaccine series and after previous COVID infection 07/25, Pfizer, dose #1 (FACILITY) 08/15, Pfizer, dose # 2 (FACILITY) 07/28 COVID swab, result: detected 12/23 COVID swab, result: detected 08/05 ABG: i-pH 7.44, i-PCO2, iPO2 39.0, i-PO2 71, i-HCO2 26.8 08/05 ddimer: 0.26 08/05 CRP: 5.582 08/05 PROCALCITONIN: <0.05 08/05 CXR IMPRESSION: Faint groundglass opacities involving the bilateral lower lobes and left upper lobe. Finding may be consistent with the patient's known positive COVID status. If further characterization is desired, consider chest CT. 08/07 ESR: 57 08/07 FIBRINOGEN: 449 08/07 DDIMER: 0.79 08/05 pt cc: exposure: unknown 08/05 pt admit Medicine cc: Cough, shortness of breath dx: hypoxemia, COVID 19 LOS: 1 day
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series and after previous COVID infection 07/25, Pfizer, dose #1 (FACILITY) 08/15, Pfizer, dose # 2 (FACILITY) 07/28 COVID swab, result: detected 12/23 COVID swab, result: detected 08/05 ABG: i-pH 7.44, i-PCO2, iPO2 39.0, i-PO2 71, i-HCO2 26.8 08/05 ddimer: 0.26 08/05 CRP: 5.582 08/05 PROCALCITONIN: <0.05 08/05 CXR IMPRESSION: Faint groundglass opacities involving the bilateral lower lobes and left upper lobe. Finding may be consistent with the patient's known positive COVID status. If further characterization is desired, consider chest CT. 08/07 ESR: 57 08/07 FIBRINOGEN: 449 08/07 DDIMER: 0.79 08/05 pt cc: exposure: unknown 08/05 pt admit Medicine cc: Cough, shortness of breath dx: hypoxemia, COVID 19 LOS: 1 day
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain upper, COVID-19, Cholelithiasis, Computerised tomogram abdomen abnormal, Gallbladder enlargement
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/30, Pfizer, dose #1 04/20, Pfizer, dose #2 01/03 COVID swab, result: detected 01/03 pt cc: epigastric, LUQ pain with vomiting, exposure: unknown 01/03 pt admit ED cc: epigastric, LUQ pain with vomiting. dx: UC, covid LOS: 1 day 01/03 us gallbladder: 1. Cholelithiasis, gallbladder wall thickening and pericholecystic fluid concerning for acute cholecystitis. No reported ultrasonographic Murphy's sign, clinical correlation if patient was provided pain medication. 2. No focal liver lesion. 01/03 CT ABD & PELVIS IMPRESSION: 1. New pericholecystic fluid in the setting of cholelithiasis. Findings can be seen with acute cholecystitis. Consider right upper quadrant ultrasound. 2. stable submucosal fat deposition within colon without findings to suggest acute colitis. 01/03 PT/INR: 11.8/1.05 01/03 TROPONIN I: <0.016 01/03 LIPASE: 17
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: International normalised ratio normal, Lipase normal, Prothrombin time normal, SARS-CoV-2 test positive, Troponin I normal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/30, Pfizer, dose #1 04/20, Pfizer, dose #2 01/03 COVID swab, result: detected 01/03 pt cc: epigastric, LUQ pain with vomiting, exposure: unknown 01/03 pt admit ED cc: epigastric, LUQ pain with vomiting. dx: UC, covid LOS: 1 day 01/03 us gallbladder: 1. Cholelithiasis, gallbladder wall thickening and pericholecystic fluid concerning for acute cholecystitis. No reported ultrasonographic Murphy's sign, clinical correlation if patient was provided pain medication. 2. No focal liver lesion. 01/03 CT ABD & PELVIS IMPRESSION: 1. New pericholecystic fluid in the setting of cholelithiasis. Findings can be seen with acute cholecystitis. Consider right upper quadrant ultrasound. 2. stable submucosal fat deposition within colon without findings to suggest acute colitis. 01/03 PT/INR: 11.8/1.05 01/03 TROPONIN I: <0.016 01/03 LIPASE: 17
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Ultrasound biliary tract, Vomiting
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/30, Pfizer, dose #1 04/20, Pfizer, dose #2 01/03 COVID swab, result: detected 01/03 pt cc: epigastric, LUQ pain with vomiting, exposure: unknown 01/03 pt admit ED cc: epigastric, LUQ pain with vomiting. dx: UC, covid LOS: 1 day 01/03 us gallbladder: 1. Cholelithiasis, gallbladder wall thickening and pericholecystic fluid concerning for acute cholecystitis. No reported ultrasonographic Murphy's sign, clinical correlation if patient was provided pain medication. 2. No focal liver lesion. 01/03 CT ABD & PELVIS IMPRESSION: 1. New pericholecystic fluid in the setting of cholelithiasis. Findings can be seen with acute cholecystitis. Consider right upper quadrant ultrasound. 2. stable submucosal fat deposition within colon without findings to suggest acute colitis. 01/03 PT/INR: 11.8/1.05 01/03 TROPONIN I: <0.016 01/03 LIPASE: 17
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Narrative:  1st moderna vaccine: 2/10/21 2nd moderna vaccine: 3/10/21 covid positive: 1/27/22 hospital stay: 1/27/22 - present day (1/31/22)
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Chest X-ray normal, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 12/30 COVID swab, result: detected 02/01 COVID swab, result: NOT detected 08/03 pt cc: exposure: unknown 02/01 CXR IMPRESSION: No radiographic evidence of acute cardiopulmonary process.
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Narrative:  1st moderna vaccine: 2/3/21 2nd moderna vaccine: 3/3/21 3rd moderna vaccine: 10/16/21 covid positive: 1/18/2022 emergency room visit due to covid related ilness: 1/25/22 hospital admission due to covid related illness: 1/31/22 (today)
Age: 78.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Narrative:  1st moderna vaccine: 1/1/2021 2nd moderna vaccine: February 2021 covid positive 1/27/22 hospital stay 1/27/22 - 1/30/22